SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 390.81 |
| Enterprise Value ($M) | 348.63 |
| Book Value ($M) | 228.49 |
| Book Value / Share | 4.23 |
| Price / Book | 1.71 |
| NCAV ($M) | 218.39 |
| NCAV / Share | 4.05 |
| Price / NCAV | 1.79 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.00 |
| Return on Assets (ROA) | -0.00 |
| Return on Equity (ROE) | -0.00 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 28.71 |
| Current Ratio | 28.71 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 232.56 |
| Assets | 242.65 |
| Liabilities | 14.16 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 80.00 |
| Operating Income | -19.83 |
| Net Income | -9.72 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -2.22 |
| Cash from Investing | 32.23 |
| Cash from Financing | 2.75 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Suvretta Capital Management, Llc | 9.40 | 48.84 | |
| 13G/A | BlackRock, Inc. | 7.50 | -27.67 | |
| 13G | Adage Capital Management, L.P. | 5.56 | ||
| 13G | Nantahala Capital Management, LLC | 7.66 | ||
| 13G/A | Rtw Investments, Lp | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 5.24 | 0.00 | |
| 13G/A | Fmr Llc | 2.76 | -69.67 | |
| 13G | TCG Crossover GP II, LLC | 9.40 | ||
| 13G/A | Ra Capital Management, L.p. | 19.30 | 84.50 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 55,970 | 340,687 | 16.43 | |
| 44,890 | 292,195 | 15.36 | |
| 55,468 | 305,754 | 18.14 | |
| 94,243 | 367,685 | 25.63 | |
| 73,876 | 342,963 | 21.54 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FATE – Fate Therapeutics, Inc. | FHTX – Foghorn Therapeutics Inc. |
| FOLD – Amicus Therapeutics, Inc. | GANX – Gain Therapeutics, Inc. |
| GHRS – GH Research PLC |
Financial data and stock pages provided by
Fintel.io